Ann: BNC105 Enhances Efficacy of Immuno-Oncology Therapies, page-7

And this from last week:


  0048 GMT [Dow Jones] Australia's Bionomics (BNO.AU) could be sitting on a new
"blockbuster drug" to treat anxiety disorders and potential depression, says
Bell Potter, which applies a A$1.09 price target on the stock--almost three times its
closing price Wednesday of A$0.39. Such mental health conditions have already been
treated by popular drugs, but patent expiries have caused an influx of cheaper generic
options. Bionomic's BNC210 could represent a new generation drug and should have
attractive licensing prospects, Bell Potter says. Results of two more clinical trials of
BNC2010 are due in the third quarters of calendar 2015 and 2016, respectively, and Bell
Potter is assuming the drug is licensed in the second half of 2017 in a deal worth US$345
million. ([email protected])


Potential blockbuster depression drug
+
Potential cancer co-therapy with 97%  tumour inhibition demonstrated
+
Demonstrated history of negotiating successful licencing deals.

I doubled my investment today.